WO2023199196 - SALTS FOR MTOR COMPOUNDS
National phase entry:
Publication Number
WO/2023/199196
Publication Date
19.10.2023
International Application No.
PCT/IB2023/053643
International Filing Date
10.04.2023
Title **
[English]
SALTS FOR MTOR COMPOUNDS
[French]
SELS POUR COMPOSÉS MTOR
Applicants **
GALDERMA HOLDING SA
Inventors
HARRIS, Craig Steven
TOMAS, Loïc Jean-Marc Frédéric
Priority Data
63/330,138
12.04.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2640 | |
| EPO | Filing, Examination, Granting | 16944 | |
| Japan | Filing, Examination, Granting | 2672 | |
| South Korea | Filing, Examination, Granting | 3038 | |
| USA | Filing, Examination, Granting | 8140 |
Total:
33,434
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present technology provides the crystalline phosphate, malonate, and malate salts of 3- (2-amino-1,3-benzoxazol-5-yl)-1-(1,3-dimethylbutyl)pyrazolo[3,4-d]pyrimidine-4,6-diamine. The present technology further provides methods for preparing the various forms, compositions containing them, and methods related to modulation of mTOR. In particular, the present crystalline compounds and compositions may be used to treat mTOR-mediated disorders and conditions, including, e.g., dermatological disorders related to a disorder of keratinization with a proliferative, inflammatory and / or immuno-allergic component.[French]
La présente technologie concerne du phosphate cristallin, du malonate et des sels malates de 3-(2-amino-1,3-benzoxazole-5-yl)-1-(1,3-diméthylbutyl)pyrazolo[3,4-d]pyrimidine-4,6-diamine. La présente technologie concerne en outre des méthodes de préparation des diverses formes, de compositions les contenant, et de méthodes associées à la modulation de mTOR. En particulier, les présents composés cristallins et compositions peuvent être utilisés pour traiter des troubles et des états médiés par mTOR, comprenant, par exemple, des troubles dermatologiques liés à un trouble de la kératinisation avec un composant prolifératif, inflammatoire et/ou immuno-allergique.